Compass Therapeutics Inc (CMPX)

$1.69 -0.55 (-24.55%)
Market Cap 309.75M
Revenue (ttm) 850,000.00
Net Income (ttm) -49.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,809.41%
Debt to Equity Ratio 0.00
Volume 5,715,300
Avg Vol 1,638,320
Day's Range N/A - N/A
Shares Out 138.28M
Stochastic %K 33%
Beta 1.40
Analysts Strong Sell
Price Target $9.11

Latest News on CMPX

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 4:05 PM EDT - 8 hours ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Apr 1, 2025, 7:00 AM EDT - 1 day ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 2 days ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 4 weeks ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 10, 2024, 8:00 AM EST - 4 months ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Dec 9, 2024, 12:54 PM EST - 4 months ago

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 4 months ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 13, 2024, 8:30 AM EST - 5 months ago

Compass Therapeutics to Participate in Upcoming Investor Events

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 12, 2024, 8:00 AM EST - 5 months ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2024, 10:05 AM EST - 5 months ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 6 months ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Aug 7, 2024, 8:00 AM EDT - 8 months ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Compass Therapeutics: Pointing Right At Some Tough Cancers

Jun 20, 2024, 3:14 AM EDT - 10 months ago

Compass Therapeutics: Pointing Right At Some Tough Cancers

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 10 months ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics Announces CEO Transition

May 28, 2024, 4:10 PM EDT - 11 months ago

Compass Therapeutics Announces CEO Transition

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 23, 2024, 5:05 PM EDT - 11 months ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 14, 2024, 8:00 AM EDT - 11 months ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 11 months ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 9, 2024, 12:00 PM EDT - 1 year ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Compass Therapeutics Provides Corporate Update

Jan 5, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Provides Corporate Update

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:30 AM EST - 1 year ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

Jun 22, 2023, 4:05 PM EDT - 1 year ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

May 4, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 19, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Feb 2, 2023, 8:30 AM EST - 2 years ago

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Jan 19, 2023, 5:00 PM EST - 2 years ago

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Jan 6, 2023, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

Dec 15, 2022, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Dec 1, 2022, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 8:00 AM EST - 2 years ago

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 9, 2022, 9:00 AM EST - 2 years ago

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Compass Therapeutics to Present at Upcoming Investment Conferences

Nov 8, 2022, 8:00 AM EST - 2 years ago

Compass Therapeutics to Present at Upcoming Investment Conferences

Compass Therapeutics Announces $80 Million Private Placement

Nov 2, 2022, 9:06 AM EDT - 2 years ago

Compass Therapeutics Announces $80 Million Private Placement

Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Sep 9, 2022, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 1, 2022, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

May 23, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 9, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

May 3, 2022, 4:01 PM EDT - 3 years ago

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Apr 8, 2022, 1:01 PM EDT - 3 years ago

Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

Mar 30, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 21, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

Jan 20, 2022, 8:30 AM EST - 3 years ago

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Jan 7, 2022, 9:00 AM EST - 3 years ago

Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference